QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:ALKS

Alkermes (ALKS) Stock Forecast, Price & News

$29.10
+0.08 (+0.28%)
(As of 09/25/2023 ET)
Compare
Today's Range
$28.70
$29.31
50-Day Range
$27.17
$31.97
52-Week Range
$21.75
$33.71
Volume
1.26 million shs
Average Volume
1.46 million shs
Market Capitalization
$4.85 billion
P/E Ratio
51.05
Dividend Yield
N/A
Price Target
$33.33

Alkermes MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
14.5% Upside
$33.33 Price Target
Short Interest
Bearish
5.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
0.82mentions of Alkermes in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
56.38%
From $0.94 to $1.47 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

378th out of 961 stocks

Pharmaceutical Preparations Industry

163rd out of 453 stocks


ALKS stock logo

About Alkermes (NASDAQ:ALKS) Stock

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Price History

ALKS Stock News Headlines

Alkermes plc (NASDAQ:ALKS) Sees Large Increase in Short Interest
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Alkermes (ALKS) Stock Moves -0.84%: What You Should Know
For Potential Alkermes Buyers, There's a Key Price Level to Watch
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
3 Best Biotech Stocks for Growth in September
Alkermes Honors Women's Equality Day
3 Biotech Stocks to Buy This Month and Beyond
Is Now the Time to Buy Into Moderna, Inc. (MRNA)?
Alkermes: A Complicated Story Right Now
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings
7/26/2023
Today
9/25/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,280
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$33.33
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+14.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-158,270,000.00
Pretax Margin
7.03%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$0.25 per share
Book Value
$6.35 per share

Miscellaneous

Free Float
158,631,000
Market Cap
$4.85 billion
Optionable
Optionable
Beta
0.60

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Richard F. PopsMr. Richard F. Pops (Age 61)
    Chairman & CEO
    Comp: $2.3M
  • Mr. Iain Michael BrownMr. Iain Michael Brown (Age 54)
    Sr. VP & CFO
    Comp: $867.75k
  • Mr. Blair C. JacksonMr. Blair C. Jackson (Age 50)
    Exec. VP & COO
    Comp: $1.05M
  • Mr. David Joseph GaffinMr. David Joseph Gaffin (Age 51)
    Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
    Comp: $1.08M
  • Dr. Craig C. Hopkinson M.D. (Age 55)
    Exec. VP of R&D and Chief Medical Officer
    Comp: $1.12M
  • Dr. Floyd E. Bloom M.D. (Age 86)
    Founder
  • Mr. Thomas Harvey
    Chief Information Officer & Sr. VP of IT
  • Ms. Sandra Coombs
    Sr. VP of Corp. Affairs & Investor Relations
  • Mr. Michael J. LandineMr. Michael J. Landine (Age 69)
    Sr. VP of Corp. Devel. & Chief Risk Officer
  • Mr. Stephen Schiavo
    Sr. VP of HR













ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price forecast for 2023?

6 analysts have issued twelve-month price targets for Alkermes' stock. Their ALKS share price forecasts range from $28.00 to $40.00. On average, they expect the company's stock price to reach $33.33 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 on January 1st, 2023. Since then, ALKS shares have increased by 11.4% and is now trading at $29.10.
View the best growth stocks for 2023 here
.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 16.0% from the August 15th total of 8,170,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 5.5 days.
View Alkermes' Short Interest
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings results on Wednesday, July, 26th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.28 by $0.10. The business had revenue of $617.40 million for the quarter, compared to the consensus estimate of $572.57 million. Alkermes had a net margin of 7.04% and a trailing twelve-month return on equity of 2.33%.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY23 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.34-$1.57 for the period, compared to the consensus estimate of $1.12. The company issued revenue guidance of $1.55-$1.68 billion, compared to the consensus revenue estimate of $1.48 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.14%), State Street Corp (3.54%), Hardman Johnston Global Advisors LLC (3.46%), Renaissance Technologies LLC (3.10%), Geode Capital Management LLC (2.00%) and Bank of New York Mellon Corp (1.59%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $29.10.

How much money does Alkermes make?

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.85 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Alkermes have?

The company employs 2,280 workers across the globe.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -